NYSE:ANRO • US02157Q1094
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ALTO NEUROSCIENCE INC (ANRO).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-22 | Chardan Capital | Maintains | Buy -> Buy |
| 2026-04-02 | Jones Trading | Maintains | Buy -> Buy |
| 2026-04-02 | Chardan Capital | Maintains | Buy -> Buy |
| 2026-04-02 | Wedbush | Maintains | Neutral -> Neutral |
| 2026-04-02 | Baird | Maintains | Outperform -> Outperform |
| 2026-04-02 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-03-18 | Baird | Maintains | Outperform -> Outperform |
| 2026-03-17 | Chardan Capital | Maintains | Buy -> Buy |
| 2026-03-17 | Wedbush | Maintains | Neutral -> Neutral |
| 2026-02-17 | BTIG | Maintains | Buy -> Buy |
| 2026-01-05 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-11-17 | BTIG | Initiate | Buy |
| 2025-11-13 | Baird | Maintains | Outperform -> Outperform |
| 2025-11-12 | Jefferies | Maintains | Buy -> Buy |
| 2025-10-24 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-20 | Baird | Maintains | Outperform -> Outperform |
| 2025-09-29 | Chardan Capital | Initiate | Buy |
| 2025-08-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-06-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-05-15 | Wedbush | Reiterate | Neutral -> Neutral |
| 2025-04-07 | HC Wainwright & Co. | Initiate | Buy |
| 2024-12-16 | Jones Trading | Initiate | Buy |
| 2024-11-13 | Stifel | Maintains | Buy -> Buy |
| 2024-10-23 | Wedbush | Downgrade | Outperform -> Neutral |
| 2024-10-23 | Baird | Maintains | Outperform -> Outperform |
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 210K | N/A -100.00% | 4.743M | 41.671M 778.58% | 261.12M 526.62% | 803.04M 207.54% | 1.373B 70.98% | 2.317B 68.75% | ||||||
| EBITDA YoY % growth | -11.911M | N/A -142.21% | N/A -29.76% | N/A -81.93% | -72.318M -6.18% | -109.752M -51.76% | -146.472M -33.46% | -196.962M -34.47% | -148.614M 24.55% | -39.372M 73.51% | N/A | N/A | N/A | |
| EBIT YoY % growth | -12.056M | N/A -142.14% | -42.2M -29.52% | -74.975M -81.46% | -68.831M -0.32% | -92.428M -34.28% | -127.637M -38.09% | -143.013M -12.05% | -136.891M 4.28% | 33.773M 124.67% | 478.32M 1,316.28% | 830.34M 73.60% | 1.203B 44.88% | |
| Operating Margin | -5,740.95% | N/A | N/A | N/A | N/A | N/A | N/A | -3,015.24% | -328.50% | 12.93% | 59.56% | 60.48% | 51.92% | |
| EPS YoY % growth | N/A | N/A | -4.78 | -2.64 46.85% | -2.29 9.06% | -2.28 1.23% | -2.78 -21.75% | -2.93 -5.56% | -2.10 28.52% | 2.18 204.14% | 4.91 124.77% | 6.11 24.53% | 9.70 58.76% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.55 2.15% | -0.60 6.98% | -0.62 -18.85% | -0.60 -3.04% | -0.67 -21.44% | -0.71 -17.88% | -0.73 -17.35% | -0.73 -22.51% |
| Revenue Q2Q % growth | N/A | N/A | N/A | N/A | ||||
| EBITDA Q2Q % growth | -24.888M -60.52% | -26.622M -45.14% | -28.254M -95.57% | -29.988M -82.92% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -20.197M -28.84% | -23.314M -24.80% | -24.241M -62.13% | -27.549M -61.53% | -25.704M -27.26% | -26.724M -14.63% | -27.744M -14.45% | -28.764M -4.41% |
All data in USD
16 analysts have analysed ANRO and the average price target is 35.57 USD. This implies a price increase of 45.08% is expected in the next year compared to the current price of 24.52.
The consensus EPS estimate for the next earnings of ALTO NEUROSCIENCE INC (ANRO) is -0.55 USD and the consensus revenue estimate is 0 USD.
The consensus rating for ALTO NEUROSCIENCE INC (ANRO) is 86.25 / 100 . This indicates that analysts generally have a positive outlook on the stock.